🔗 bit.ly/46kajHr
@simonfeys.bsky.social @agocarvalho.bsky.social @martinhoenigl.bsky.social
🔗 bit.ly/46kajHr
@simonfeys.bsky.social @agocarvalho.bsky.social @martinhoenigl.bsky.social
👉 bit.ly/medical-myco...
👉 bit.ly/medical-myco...
journals.lww.com/jaids/abstra...
journals.lww.com/jaids/abstra...
Histoplasma antigenuria prevalence in patients with advanced HIV disease in Côte d’Ivoire: a prospective trial ancillary study
Histoplasma antigenuria is prevalent in persons with advanced HIV in Côte d’Ivoire
academic.oup.com/cid/advance-...
Histoplasma antigenuria prevalence in patients with advanced HIV disease in Côte d’Ivoire: a prospective trial ancillary study
Histoplasma antigenuria is prevalent in persons with advanced HIV in Côte d’Ivoire
academic.oup.com/cid/advance-...
✅ Just Accepted
✍️ @GermHunterMD.bsky.social
#IDSky
✅ Just Accepted
✍️ @GermHunterMD.bsky.social
#IDSky
✅ Just Accepted
⭐ Editor's Choice
#IDSky
✅ Just Accepted
⭐ Editor's Choice
#IDSky
Our tool can estimate extent to which misallocation of person time will result in spurious or optimistic estimates of intervention effects
We find benefits of IVIG in STSS have likely been exaggerated
Our tool can estimate extent to which misallocation of person time will result in spurious or optimistic estimates of intervention effects
We find benefits of IVIG in STSS have likely been exaggerated
This comprehensive review explores the scientific foundations behind treatment duration, identifies key knowledge gaps, and highlights critical future directions in the field. Don’t miss it! 🔥
#IDSky
www.sciencedirect.com/science/arti...
This comprehensive review explores the scientific foundations behind treatment duration, identifies key knowledge gaps, and highlights critical future directions in the field. Don’t miss it! 🔥
#IDSky
www.sciencedirect.com/science/arti...
Lots of cryptococcal meningitis in this cohort (40-60% of those with proven diagnoses), mortality similar to trials
www.thelancet.com/journals/lan...
Lots of cryptococcal meningitis in this cohort (40-60% of those with proven diagnoses), mortality similar to trials
www.thelancet.com/journals/lan...